BJDX logo

Bluejay Diagnostics, Inc. Stock Price

NasdaqCM:BJDX Community·US$1.9m Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 0 Fair Values set on narratives written by author

BJDX Share Price Performance

US$0
-14.80 (-100.00%)
US$0
-14.80 (-100.00%)
Price US$0

BJDX Community Narratives

There are no narratives available yet.

Trending Discussion

Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Flawless balance sheet with moderate risk.

5 Risks
0 Rewards

Bluejay Diagnostics, Inc. Key Details

US$0

Revenue

US$0

Cost of Revenue

US$0

Gross Profit

US$6.8m

Other Expenses

-US$6.8m

Earnings

Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
-6.62
0%
0%
0%
View Full Analysis

About BJDX

Founded
2015
Employees
6
CEO
Indranil Dey
WebsiteView website
bluejaydx.com

Bluejay Diagnostics, Inc. operates as a medical diagnostics company. It offers Symphony technology platform which consists of an analyzer and single-use protein detection cartridges that are designed to provide measurements of key diagnostic biomarkers found in blood; and Symphony analyzer used to orchestrate sample processing of whole blood, plasma, serum, etc., biomarker isolation, and immunoassay preparation using non-contact centrifugal force. The company also develops Symphony IL-6 tests for the monitoring of disease progression in critical care settings. In addition, it develops additional tests for Symphony, such as tests for myocardial infraction and congestive heart failure, as well as other tests using the Symphony platform. Bluejay Diagnostics, Inc. was incorporated in 2015 and is headquartered in Acton, Massachusetts.

Recent BJDX News & Updates

Recent updates

No updates